Update: CARB-X Grants Antabio Additional €4M to Develop Cystic Fibrosis Antibiotic
Update (03/01/2020): The global non-profit partnership CARB-X has awarded Antabio €4M ($4.4M) as a second…
Update (03/01/2020): The global non-profit partnership CARB-X has awarded Antabio €4M ($4.4M) as a second…
Update (30/01/2018): Oxford Nanopore has published a study in Nature Biotechnology outlining the first use of…
Six European countries, the UK's Wellcome Trust and South Africa have committed €56.5M to the…
The UK's Wellcome trust has selected 22 pictures and images that capture the wonders of…
Mucosis is starting Phase I trials for SynGEM, a needle-free vaccine against RSV, which causes…
Cancer Research UK has teamed up with MSD (Merck) and the Wellcome Trust to co-develop some…
Choroideremia is a rare X-linked recessive retinal disease which eventually leads to blindness. A series…
Now, as we've recently discussed here at Labiotech, there doesn't appear to be many Welsh…
The Francis Crick Institute from London has announced its application to conduct non-clinical purpose research…
Respiratory Syncytial Virus (RSV) affects millions annually, therefore attracting many large biotechs to research a…
Kymab is the European biotech to watch! Based in Cambridge (UK), the company has developed the Kymouse…